Costello also holds the dual positions of company secretary and chief financial officer.
Her appointment as executive director follows the resignation of Mathew Ratty and fulfils the requirement to have two resident Australian directors.
Admedus has commenced the search for another permanent Australian resident director to replace Ratty.
The company has filed three new provisional patent applications in the US as part of its transcatheter aortic valve replacement (TAVR) research and development project.
TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.
Admedus’ new TAVR device is designed to reduce the risks associated with the insertion and placement of the valve.